2021
DOI: 10.1002/pd.6032
|View full text |Cite
|
Sign up to set email alerts
|

Non‐invasive prenatal testing 10 years on

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 34 publications
0
3
0
Order By: Relevance
“…Currently, NIPT is widely utilized in clinical routine screening for trisomy 21, trisomy 18, and trisomy 13 [6,7] , demonstrating high accuracy and specificity. However, there is a lack of consensus on the screening conclusions for sex chromosome abnormalities, leading to controversy over whether NIPT should be extended to routine screening for such abnormalities.…”
Section: Discussionmentioning
confidence: 99%
“…Currently, NIPT is widely utilized in clinical routine screening for trisomy 21, trisomy 18, and trisomy 13 [6,7] , demonstrating high accuracy and specificity. However, there is a lack of consensus on the screening conclusions for sex chromosome abnormalities, leading to controversy over whether NIPT should be extended to routine screening for such abnormalities.…”
Section: Discussionmentioning
confidence: 99%
“…The American College of Obstetrics and Gynecology (ACOG) recommends non-invasive prenatal screening for all women, regardless of maternal age ( American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics, 2020 ). In addition to detecting trisomies for chromosomes 21, 18, and 13 and sex chromosome aneuploidies, expanded NIPS tests based on a whole-genome assessment of cell-free DNA in maternal plasma are able to identify rare autosomal trisomies (RATs), known microdeletions/duplications, and rare copy number and structural variants ( Chitty, 2021 ). Recent reports in the literature describe and discuss the detection of marker chromosomes by NIPS ( Luo et al, 2020 ; Liehr, 2021 ).…”
Section: Discussionmentioning
confidence: 99%
“…cffDNA is a small-sized fragmented DNA (<200 bp) of placental origin that accounts for 3–20% of maternal circulation DNA [ [15] , [16] , [17] , [18] , [19] ]. The amount of free fetal DNA varies throughout the pregnancy [ 2 ].…”
Section: Expanding Scope Of Non-invasive Prenatal Screeningmentioning
confidence: 99%